Royalty Pharma plc (RPRX) vs Zoetis Inc. (ZTS)
Royalty Pharma plc and Zoetis Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — RPRX vs ZTS, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Royalty Pharma plc (RPRX) | Zoetis Inc. (ZTS) | |
|---|---|---|
| Market cap | $31.6B | $32.1B |
| Revenue (latest FY) | $2.38B | $9.47B |
| Net income (latest FY) | $770.95M | $2.67B |
| Revenue growth (5y CAGR) | 2.3% | 7.2% |
| Net margin | 32.4% | 28.2% |
| Return on equity | 11.9% | 78.3% |
| P/E ratio | 28.9 | 12.7 |
| Dividend yield | 1.7% | 2.7% |
| Profitable years (of last 10) | 8 | 10 |
| Positive free cash flow | — | Yes |
Performance — RPRX vs ZTS
Total returns from monthly split- and dividend-adjusted closes; 52-week range from the latest quote. Past performance is not a prediction.
| Royalty Pharma plc (RPRX) | Zoetis Inc. (ZTS) | |
|---|---|---|
| 1-year return | 55.8% | -49.6% |
| 3-year return | 93.5% | -57.7% |
| 5-year return | 50.7% | -60.0% |
| 10-year return | — | 65.2% |
| 52-week range | $34.08–$56.50 | $71.00–$155.38 |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full RPRX vs ZTS breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open RPRX's full financials → Open ZTS's full financials →More comparisons
Frequently asked questions
Which is bigger, RPRX or ZTS?
Zoetis Inc. is larger by market capitalization — $32.1B versus $31.6B.
Which grows faster, RPRX or ZTS?
Over the last five fiscal years, Zoetis Inc. grew revenue faster — 7.2%/yr versus 2.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.